Drugs / GSK424887
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01424384 | Sep 2008 → Apr 2009 | mixed anxiety and depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01059591 | May 2006 → Jan 2007 | mixed anxiety and depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK424887 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01059591 ↗ |
| Action | Inhibit | “a potent, selective competitive antagonist of the human Neurokinin 1 (NK1) receptor and a potent inhibitor of the human serotonin transporter (SERT)” NCT01424384 ↗ |
| Modality | Small molecule | — CHEMBL4297387 ↗ |
| Route | Oral | “following oral administration of GSK424887” NCT01424384 ↗ |